Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02880293 · ClinicalTrials.gov registry record · NA
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT02880293: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02880293 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02880293, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG fludarabine
- DRUG melphalan
- DRUG thiotepa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-08-23 |
| Est. Completion | 2023-11-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02880293
The ClinicalTrials.gov registry entry for NCT02880293 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02880293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02880293 about?
NCT02880293 is a clinical study titled "Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor". This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
What is the current status of trial NCT02880293?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2016-08-23. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT02880293?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), fludarabine (DRUG), melphalan (DRUG), thiotepa (DRUG).
Who is sponsoring clinical trial NCT02880293?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.